Trends of Antiplatelet Therapy for the Management of Moyamoya Disease in Japan: Results of a Nationwide Survey

Research Committee on Spontaneous Occlusion of Circle of Willis (Moyamoya disease)

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The efficacy and safety of antiplatelet drugs in the treatment of moyamoya disease remain unclear. This study reports results of a nationwide survey conducted in 2016 on the trends of antiplatelet therapy for moyamoya disease in Japan. Methods: Data were obtained through questionnaires related to treatment policies regarding antiplatelet drugs from each specialized stroke management department of 765 hospitals in Japan. Data were also compared between experienced facilities (defined as facilities managing more than 10 cases per year) and those less experienced (not more than 10 cases per year) to determine experts' opinion. Results: Of the 389 departments in 375 hospitals that responded, 330 departments provided medical care for moyamoya disease. Regarding ischemic stroke, numerous departments considered the use of antiplatelet drugs “in principle” (218 departments). After surgery for ischemic moyamoya disease, the use of antiplatelet drugs for a certain period of time was the most popular opinion (74 departments). Regarding asymptomatic moyamoya disease, majority departments reported no use of APDs “in principle” (256 departments). The experienced facilities reported “no use of antiplatelet drugs” more frequently than those less experienced for treating asymptomatic moyamoya disease. In moyamoya disease, aspirin was the most commonly used antiplatelet drugs followed by cilostazol and clopidogrel. Conclusions: This survey revealed details of treatment policies, and the selection of antiplatelet drugs widely varied across facilities. Further prospective studies are necessary to improve the current unclear situation regarding the use of antiplatelet drugs for the management of moyamoya disease.

Original languageEnglish
Pages (from-to)3605-3612
Number of pages8
JournalJournal of Stroke and Cerebrovascular Diseases
Volume27
Issue number12
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Moyamoya Disease
Platelet Aggregation Inhibitors
Japan
Asymptomatic Diseases
pamidronate
clopidogrel
Therapeutics
Stroke
Surveys and Questionnaires
Hospital Departments
Expert Testimony
Aspirin
Prospective Studies
Safety

Keywords

  • antiplatelet drugs
  • aspirin
  • cilostazol
  • clopidogrel
  • Moyamoya disease
  • nationwide survey

ASJC Scopus subject areas

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Trends of Antiplatelet Therapy for the Management of Moyamoya Disease in Japan : Results of a Nationwide Survey. / Research Committee on Spontaneous Occlusion of Circle of Willis (Moyamoya disease).

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 27, No. 12, 01.12.2018, p. 3605-3612.

Research output: Contribution to journalArticle

Research Committee on Spontaneous Occlusion of Circle of Willis (Moyamoya disease). / Trends of Antiplatelet Therapy for the Management of Moyamoya Disease in Japan : Results of a Nationwide Survey. In: Journal of Stroke and Cerebrovascular Diseases. 2018 ; Vol. 27, No. 12. pp. 3605-3612.
@article{91a2145d3398486686754bf3bc5dc3cc,
title = "Trends of Antiplatelet Therapy for the Management of Moyamoya Disease in Japan: Results of a Nationwide Survey",
abstract = "Background: The efficacy and safety of antiplatelet drugs in the treatment of moyamoya disease remain unclear. This study reports results of a nationwide survey conducted in 2016 on the trends of antiplatelet therapy for moyamoya disease in Japan. Methods: Data were obtained through questionnaires related to treatment policies regarding antiplatelet drugs from each specialized stroke management department of 765 hospitals in Japan. Data were also compared between experienced facilities (defined as facilities managing more than 10 cases per year) and those less experienced (not more than 10 cases per year) to determine experts' opinion. Results: Of the 389 departments in 375 hospitals that responded, 330 departments provided medical care for moyamoya disease. Regarding ischemic stroke, numerous departments considered the use of antiplatelet drugs “in principle” (218 departments). After surgery for ischemic moyamoya disease, the use of antiplatelet drugs for a certain period of time was the most popular opinion (74 departments). Regarding asymptomatic moyamoya disease, majority departments reported no use of APDs “in principle” (256 departments). The experienced facilities reported “no use of antiplatelet drugs” more frequently than those less experienced for treating asymptomatic moyamoya disease. In moyamoya disease, aspirin was the most commonly used antiplatelet drugs followed by cilostazol and clopidogrel. Conclusions: This survey revealed details of treatment policies, and the selection of antiplatelet drugs widely varied across facilities. Further prospective studies are necessary to improve the current unclear situation regarding the use of antiplatelet drugs for the management of moyamoya disease.",
keywords = "antiplatelet drugs, aspirin, cilostazol, clopidogrel, Moyamoya disease, nationwide survey",
author = "{Research Committee on Spontaneous Occlusion of Circle of Willis (Moyamoya disease)} and Koichi Oki and Masahiro Katsumata and Yoshikane Izawa and Shinichi Takahashi and Norihiro Suzuki and Kiyohiro Houkin",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.jstrokecerebrovasdis.2018.08.030",
language = "English",
volume = "27",
pages = "3605--3612",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Trends of Antiplatelet Therapy for the Management of Moyamoya Disease in Japan

T2 - Results of a Nationwide Survey

AU - Research Committee on Spontaneous Occlusion of Circle of Willis (Moyamoya disease)

AU - Oki, Koichi

AU - Katsumata, Masahiro

AU - Izawa, Yoshikane

AU - Takahashi, Shinichi

AU - Suzuki, Norihiro

AU - Houkin, Kiyohiro

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: The efficacy and safety of antiplatelet drugs in the treatment of moyamoya disease remain unclear. This study reports results of a nationwide survey conducted in 2016 on the trends of antiplatelet therapy for moyamoya disease in Japan. Methods: Data were obtained through questionnaires related to treatment policies regarding antiplatelet drugs from each specialized stroke management department of 765 hospitals in Japan. Data were also compared between experienced facilities (defined as facilities managing more than 10 cases per year) and those less experienced (not more than 10 cases per year) to determine experts' opinion. Results: Of the 389 departments in 375 hospitals that responded, 330 departments provided medical care for moyamoya disease. Regarding ischemic stroke, numerous departments considered the use of antiplatelet drugs “in principle” (218 departments). After surgery for ischemic moyamoya disease, the use of antiplatelet drugs for a certain period of time was the most popular opinion (74 departments). Regarding asymptomatic moyamoya disease, majority departments reported no use of APDs “in principle” (256 departments). The experienced facilities reported “no use of antiplatelet drugs” more frequently than those less experienced for treating asymptomatic moyamoya disease. In moyamoya disease, aspirin was the most commonly used antiplatelet drugs followed by cilostazol and clopidogrel. Conclusions: This survey revealed details of treatment policies, and the selection of antiplatelet drugs widely varied across facilities. Further prospective studies are necessary to improve the current unclear situation regarding the use of antiplatelet drugs for the management of moyamoya disease.

AB - Background: The efficacy and safety of antiplatelet drugs in the treatment of moyamoya disease remain unclear. This study reports results of a nationwide survey conducted in 2016 on the trends of antiplatelet therapy for moyamoya disease in Japan. Methods: Data were obtained through questionnaires related to treatment policies regarding antiplatelet drugs from each specialized stroke management department of 765 hospitals in Japan. Data were also compared between experienced facilities (defined as facilities managing more than 10 cases per year) and those less experienced (not more than 10 cases per year) to determine experts' opinion. Results: Of the 389 departments in 375 hospitals that responded, 330 departments provided medical care for moyamoya disease. Regarding ischemic stroke, numerous departments considered the use of antiplatelet drugs “in principle” (218 departments). After surgery for ischemic moyamoya disease, the use of antiplatelet drugs for a certain period of time was the most popular opinion (74 departments). Regarding asymptomatic moyamoya disease, majority departments reported no use of APDs “in principle” (256 departments). The experienced facilities reported “no use of antiplatelet drugs” more frequently than those less experienced for treating asymptomatic moyamoya disease. In moyamoya disease, aspirin was the most commonly used antiplatelet drugs followed by cilostazol and clopidogrel. Conclusions: This survey revealed details of treatment policies, and the selection of antiplatelet drugs widely varied across facilities. Further prospective studies are necessary to improve the current unclear situation regarding the use of antiplatelet drugs for the management of moyamoya disease.

KW - antiplatelet drugs

KW - aspirin

KW - cilostazol

KW - clopidogrel

KW - Moyamoya disease

KW - nationwide survey

UR - http://www.scopus.com/inward/record.url?scp=85056784344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056784344&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2018.08.030

DO - 10.1016/j.jstrokecerebrovasdis.2018.08.030

M3 - Article

C2 - 30220629

AN - SCOPUS:85056784344

VL - 27

SP - 3605

EP - 3612

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 12

ER -